Zafrens
PrivateLast Round
Series A
Feb 4, 2025
Total Funding Raised
$71.16M
Company Overview
Zafrens operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in February 2025.
Zafrens is a biotechnology company that develops an ultra-high throughput platform for single-cell analysis and drug discovery by integrating biology, chemistry, and engineering.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zafrens Comparables
Compare Zafrens with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Singleron Biotechnologies | 77% | |
| Mission Bio | 76% | |
| Bruker | 72% |
For institutional investors. Book with your work email.
Zafrens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 4, 2025 | ||||
| Series A | Dec 11, 2023 | ||||
| Seed | Dec 30, 2021 |
For institutional investors. Book with your work email.
Zafrens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Iaso Ventures | Series A |
| KOFA Healthcare | Series A |
| BlueYard Capital | Series A |
| FoundersX Ventures | Series A |
| Global Brain Corporation | Series A |
| Alix Ventures | Series A |
| Hawktail Management | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 4, 2025
$31M round with participation from BlueYard Capital and others.
- Dec 11, 2023
$31M round led by Prime Movers Lab.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 3, 2026
Zafrens Inc. plans to appoint Bita Sehat, Ph.D., Partner at Trill Impact Advisory, to its Board of Directors in conjunction with the financing.
- hiresNov 3, 2026
Zafrens Inc. recently hires Joey Azofeifa as Chief Technology Officer, bringing a decade of experience in computational biology, AI-driven drug discovery, and biotechnology entrepreneurship.
- receives_financingNov 3, 2026
Zafrens Inc. receives $6M Series A1 financing in a Series A extension round led by Trill Impact Ventures alongside existing investor imec.xpand to advance its internal drug pipeline and expand the Z-Screen platform.
For institutional investors. Book with your work email.
Zafrens Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zafrens's valuation, stock price, and market status.
Is Zafrens a public or private company?
Zafrens is a private company.
What is the current stock price of Zafrens?
Zafrens is a private company, so its shares have no public market price. Caplight tracks Zafrens's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zafrens worth (valuation)?
Valuation information for Zafrens is not publicly available.
Can I buy Zafrens stock?
Zafrens shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zafrens's last funding round?
Zafrens's most recent funding round was Series A on February 4, 2025.
Who are the main investors in Zafrens?
Key investors in Zafrens include Prime Movers Lab.
Will Zafrens IPO soon?
No public IPO plans have been announced for Zafrens.
How can I track Zafrens secondary market activity?
Caplight tracks bids, offers, and trades in Zafrens's shares on secondary markets.